Guggenheim Maintains Buy on GoodRx Holdings, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Sandy Draper maintains a Buy rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $8 to $10.
August 10, 2023 | 7:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst maintains a Buy rating on GoodRx Holdings and raises the price target from $8 to $10.
The news of Guggenheim maintaining a Buy rating and raising the price target for GoodRx Holdings is likely to have a positive impact on the company's stock in the short term. This is because it signals the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100